Literature DB >> 2954818

Comparative in vitro activity of A-56268 (TE-031) against gram-positive and gram-negative bacteria and Chlamydia trachomatis.

C Benson, J Segreti, H Kessler, D Hines, L Goodman, R Kaplan, G Trenholme.   

Abstract

The in vitro activity of A-56268 (TE-031) was determined and compared with that of 13 antibiotics against 401 gram-positive and gram-negative bacteria and 11 strains of Chlamydia trachomatis. A-56268 was very active against methicillin-susceptible Staphylococcus aureus and Neisseria gonorrhoeae, and was among the most active of the agents tested against Listeria monocytogenes, streptococci and Chlamydia trachomatis. It was moderately active against Haemophilus spp., Vibrio spp., Campylobacter jejuni and Campylobacter fetus subsp. fetus. It was inactive against enterococci, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Campylobacter coli, Salmonella spp., Shigella spp. and Yersinia enterocolitica. A-56268 was not consistently bactericidal or more active than erythromycin for any organism except Chlamydia trachomatis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2954818     DOI: 10.1007/bf02018203

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  3 in total

1.  Antibacterial activity of Ro 17-2301 and other antimicrobial agents against cefotaxime-resistant aerobic gram-negative bacilli.

Authors:  C A Benson; F E Walton; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

2.  Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci.

Authors:  C Thornsberry; L K McDougal
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

3.  In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis.

Authors:  J Segreti; H A Kessler; K S Kapell; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

  3 in total
  3 in total

1.  Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patients.

Authors:  H Jablonowski; G Fätkenheuer; M Youle; T Newell; S Lines; J C Craft
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 2.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 3.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.